Caribou Biosciences, Inc. · NASDAQ:CRBU
Caribou Biosciences — Technical Presentation (July 2023)
11 slides from Caribou Biosciences's technical presentation, Jul 13, 2023
Slide 1: ANTLER Phase 1 trial results summary
ANTLER Phase 1 trial results summary Transformative genome-edited therapies for patients July 13, 2023
Slide 2: Forward-looking statements
2 ANTLER trial results summary | July 2023 ©2023 Caribou Biosciences, Inc. Forward-looking statements All statements in this presentation, other than statements of historical facts, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forw
Slide 3: CB-010 dose escalation data rival approved autologous CAR-T cell therapies
3 ANTLER trial results summary | July 2023 ©2023 Caribou Biosciences, Inc. 94% overall response rate (ORR)1 69% complete response (CR) rate2 CB-010 dose escalation data rival approved autologous CAR-T cell therapies 44% complete response (CR) rate ≥6 months3 1 94% ORR measures number of patients (15
Slide 4: Patients in ANTLER all had aggressive r/r B-NHL
4 ANTLER trial results summary | July 2023 ©2023 Caribou Biosciences, Inc. Patients in ANTLER all had aggressive r/r B-NHL Patients’ baseline and disease characteristics DLBCL: diffuse large B cell lymphoma; FL: follicular lymphoma; HGBL: high-grade B cell lymphoma; MCL: mantle cell lymphoma; MZL: m
Slide 5: CB-010 has generally well-tolerated safety profile
5 ANTLER trial results summary | July 2023 ©2023 Caribou Biosciences, Inc. CB-010 has generally well-tolerated safety profile No DLTs at dose level 2 or dose level 3, no Grade 3+ CRS, no GvHD observed (N=16) AE: adverse event; CRS: cytokine release syndrome; DLT: dose-limiting toxicity; GvHD: graft-
Slide 6: CB-010 ANTLER dose escalation efficacy assessment
6 ANTLER trial results summary | July 2023 ©2023 Caribou Biosciences, Inc. DLBCL: diffuse large B cell lymphoma; FL: follicular lymphoma; HGBL: high-grade B cell lymphoma; MCL: mantle cell lymphoma; MZL: marginal zone lymphoma; PMBCL: primary mediastinal large B cell lymphoma 1 Aggressively behaving
Slide 7: Subgroup efficacy profile supports 2L LBCL clinical development
7 ANTLER trial results summary | July 2023 ©2023 Caribou Biosciences, Inc. Subgroup efficacy profile supports 2L LBCL clinical development r/r B-NHL r/r LBCL2 2L LBCL3 Endpoints N, (%) All patients (N=16) Subgroup (N=10) Subgroup (N=4) Overall response rate (ORR)1 15 (94%) 9 (90%) 4 (100%) Complete
Slide 8: Potential to address high unmet medical need in 2L LBCL
8 ANTLER trial results summary | July 2023 ©2023 Caribou Biosciences, Inc. Potential to address high unmet medical need in 2L LBCL 71% 10% 11% 5% HGBL PMBCL tFL 3% tCLL ~32.4K patients DLBCL ~32.4K patientsDiagnosed 1L ~30.8K patients 2L ~10.0K patients 3L ~4.4K patients LBCL patient treatment journ
Slide 9: Dose escalation data support ANTLER dose expansion
9 ANTLER trial results summary | July 2023 ©2023 Caribou Biosciences, Inc. Dose escalation data support ANTLER dose expansion 1 94% ORR measures number of patients (15 of 16) achieving either a CR or partial response (PR) at any time point after treatment with CB-010. 2 69% CR rate measures the numb
Slide 10: CB-010 ANTLER dose escalation efficacy assessment by dose level
10 ANTLER trial results summary | July 2023 ©2023 Caribou Biosciences, Inc. CB-010 ANTLER dose escalation efficacy assessment Overall, r/r, and 2L LBCL subgroups, by dose level 1 Certain patients converted from a CR or partial response (PR) to progressive disease (PD) at various assessment time poin
Slide 11: CB-010 is generally well tolerated
11 ANTLER trial results summary | July 2023 ©2023 Caribou Biosciences, Inc. CB-010 is generally well tolerated Treatment-emergent adverse events (TEAE) 1 TEAEs are defined as adverse events (AEs) with a start date on or after the CB-010 infusion date. 2 Encephalopathy and Grade 4 ICANS events were r
Caribou Biosciences — Technical Presentation (July 2023) on 6ix